pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2007-0-5-88-93pulmo-1983Research ArticleОБЗОРЫREVIEWРезультаты исследования TORCH: новая эпоха в терапии ХОБЛResults of the TORCH trial: a new era in the therapy of COPDАйсановЗ. Р.AisanovZ. R.
г. Москва
КалмановаЕ. Н.KalmanovaE. N.
г. Москва
ФГУ НИИ пульмонологии РосздраваRussian Federation200728102007058893Copyright © Айсанов З.Р., Калманова Е.Н., 20072007Айсанов З.Р., Калманова Е.Н.Aisanov Z.R., Kalmanova E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/1983
.
.
ReferencesGlobal initiative for chronic obstructive lung disease home page. (Accessed February 1, 2007, at www.goldcopd.org.)Global initiative for chronic obstructive lung disease home page. (Accessed February 1, 2007, at www.goldcopd.org.)Jemal A., Ward E., Hao Y., Thun M. Trends in the leading causes of death in the United States, 1970–2002. J. A. M. A. 2005; 294: 1255–1259.Jemal A., Ward E., Hao Y., Thun M. Trends in the leading causes of death in the United States, 1970–2002. J. A. M. A. 2005; 294: 1255–1259.Anthonisen N.R., Connett J.E., Murray R.P., for the Lung Health Study Research Group. Smoking and lung function of Lung Health Study participants after 11 years. Am. J. Respir. Crit. Care Med. 2002; 166: 675–679.Anthonisen N.R., Connett J.E., Murray R.P., for the Lung Health Study Research Group. Smoking and lung function of Lung Health Study participants after 11 years. Am. J. Respir. Crit. Care Med. 2002; 166: 675–679.Crockett A.J., Cranston J.M., Moss J.R., Alpers J.H. Survival on long-term oxygen therapy in chronic airflow limitation: from evidence to outcomes in the routine clinical setting. Intern. Med. J. 2001; 31: 448–454.Crockett A.J., Cranston J.M., Moss J.R., Alpers J.H. Survival on long-term oxygen therapy in chronic airflow limitation: from evidence to outcomes in the routine clinical setting. Intern. Med. J. 2001; 31: 448–454.Fishman A., Martinez F., Naunheim K. et al. National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N. Engl. J. Med. 2003; 348: 2059–2073.Fishman A., Martinez F., Naunheim K. et al. National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N. Engl. J. Med. 2003; 348: 2059–2073.Sin D., Tu J. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 580–584.Sin D., Tu J. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 580–584.Soriano J.B., Vestbo J., Pride N.B. et al. Survival in COPD patients after use of salmeterol and/or fluticasone propionate in general practice. Eur. Respir. J. 2002; 20: 819–825.Soriano J.B., Vestbo J., Pride N.B. et al. Survival in COPD patients after use of salmeterol and/or fluticasone propionate in general practice. Eur. Respir. J. 2002; 20: 819–825.Waterhouse J.C., Fishwick D., Anderson J.A. et al. What caused death in the ISOLDE study? Eur. Respir. J. 1999; 14 (suppl. 30): 387s.Waterhouse J.C., Fishwick D., Anderson J.A. et al. What caused death in the ISOLDE study? Eur. Respir. J. 1999; 14 (suppl. 30): 387s.Sin D.D., Anthonisen N.R., Soriano J.B., Agusti A.G. Mortality in COPD: role of comorbidities. Eur. Respir. J. 2006; 28 (6): 1245–57.Sin D.D., Anthonisen N.R., Soriano J.B., Agusti A.G. Mortality in COPD: role of comorbidities. Eur. Respir. J. 2006; 28 (6): 1245–57.Vestbo J., TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. Eur. Respir. J. 2004; 24: 206–210.Vestbo J., TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. Eur. Respir. J. 2004; 24: 206–210.Burge P., Calverley P., Jones P. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Brit. Med. J. 2000; 320: 1297–1303.Burge P., Calverley P., Jones P. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Brit. Med. J. 2000; 320: 1297–1303.Calverley P.M.A., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449–456.Calverley P.M.A., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449–456.Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74–81.Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74–81.Calverley P.M.A., Anderson J.A., Celli B. et al. for the TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356 (8): 775–789 & Online Supplements.Calverley P.M.A., Anderson J.A., Celli B. et al. for the TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356 (8): 775–789 & Online Supplements.Altman D.G. Practical statistics for medical research. London: Chapman and Hall; 1991.Altman D.G. Practical statistics for medical research. London: Chapman and Hall; 1991.Pocock S.J. Clinical trials. London John: Wiley and Sons; 1984; 205.Pocock S.J. Clinical trials. London John: Wiley and Sons; 1984; 205.Shakespeare T.P., Gebski V.J., Veness M.J., Simes J. Improving interpretation of clinical studies by use of confidence levels, clinical significance curves and risk-benefit contours. Lancet 2001; 357: 1349–1353.Shakespeare T.P., Gebski V.J., Veness M.J., Simes J. Improving interpretation of clinical studies by use of confidence levels, clinical significance curves and risk-benefit contours. Lancet 2001; 357: 1349–1353.Anthonisen N.R., Skeans M.A., Wise R.A. et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142: 233–239.Anthonisen N.R., Skeans M.A., Wise R.A. et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142: 233–239.Flather M.D., Yusuf S., Kober L. et al. Long term ACEinhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000; 355: 1575–1581.Flather M.D., Yusuf S., Kober L. et al. Long term ACEinhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000; 355: 1575–1581.Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch. Intern. Med. 2004; 164: 1427–1436.Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch. Intern. Med. 2004; 164: 1427–1436.http://www.lakemedelsverket.se/upload/SPC_PIL/Pdf/enhumspc/Symbicort%20forte%20Turbuhaler%20inhalation%20powder%20ENG.pdfhttp://www.lakemedelsverket.se/upload/SPC_PIL/Pdf/enhumspc/Symbicort%20forte%20Turbuhaler%20inhalation%20powder%20ENG.pdf
The authors declare that there are no conflicts of interest present.